Institute of Hematology and Blood Transfusion, Czech Republic Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01375868
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institute of Hematology and Blood Transfusion, Czech Republic

Active Ingredients

Drugs in Phase 3 Trials (1)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Drugs in Phase 2 Trials (2)

blinatumomab (blincyto) (1 trial)

ponatinib (iclusig) (1 trial)

Drugs in Phase 1 Trials (1)

cd19 car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Papilloma (Phase 3)

Papillomavirus Infections (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4